Clinical Utility and Impact of Phosphatidylethanol Testing in Liver Transplantation Evaluations

Abstract

BackgroundPhosphatidylethanol (PEth) is a serum biomarker that can detect alcohol use within the last 28 days with excellent sensitivity and specificity. Urinary ethyl glucuronide (uEtG) is commonly used in transplant settings to screen for alcohol use; however, it has several limitations relevant to liver transplantation. Transplant centers are beginning to regularly utilize PEth as part of the screening process for high-risk liver transplantation candidates, though the clinical utility of uniform pre-transplant PEth testing is unclear. MethodsThis was a retrospective chart review of all patients evaluated for liver transplantation from December 1, 2019, through May 31, 2022 at a large academic tertiary referral center utilizing uniform serum PEth and uEtG screening. Information regarding the patients’ transplantation status, age, sex, race, MELD Score, and PEth levels were obtained. In those with a positive PEth, we examined if the result would have been detected with uEtG, identified a discrepancy from the documented patient report of last use, led to a change in Psychosocial Assessment of Candidate for Transplantation (PACT) score, or influenced the transplant selection committee’s decision. ResultsOur sample included 865 individuals (mean age=55.20, 61.27% male and 82.54% white) with calculated MELDNa scores ranged from 6.43-50.65 (Mean 18.09; Median: 16.46). Forty-eight patients were found to have a positive PEth (PEth range 20-1833); 75% of the sample had Alcohol-associated Liver Disease (ALD). In 23/48 (47.91%) of cases, the positive PEth identified alcohol use missed by a concomitant uEtG screen. A positive PEth test identified a discrepancy from patients’ self-report in 29 (60.42%) cases and influenced the selection committee’s decision in 28 cases (58.33%). ConclusionUniform pre-transplant PEth screening of liver transplant candidates at the time of initial evaluation identified alcohol use that would have been missed by uEtG testing, identified discrepancies from the patient’s self-report, and influenced clinical decision making in a significant number of cases. These findings support the use of uniform PEth screening in Liver Transplantation Evaluations.